Intrahospital Influenza Vaccination in Patients at High Cardiovascular Risk (VACC-UP)

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorStephan Baldus

About this trial

The aim of this study is to evaluate the effect of offering intrahospital influenza vaccination as an adjunct to active counseling during the index hospitalization to adult patients hospitalized for acute coronary syndrome (ACS) or congestive heart failure (CHF), compared with active counseling alone, on influenza vaccination rates in patients at high cardiovascular risk.

Patients are randomized 1:1 to either an offer of bedside intrahospital influenza vaccination according to the recommendations of the German Standing Vaccination Committee (STIKO) in addition to standardized active counseling (intervention group), or standardized active counseling plus the standard-of-care recommendation for ambulatory vaccination in the discharge papers (control group). The primary endpoint is the influenza vaccination rate at the end of the index season (March 31).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 years or older

Hospitalized due to acute coronary syndrome (ACS) or congestive heart failure (CHF) and fulfilling the criteria for influenza vaccination according to the recommendations of the German Standing Vaccination Committee (STIKO)

Written informed consent

Disqualifiers

Already received seasonal influenza vaccination in the current season, based on self-reported vaccination status and/or vaccination certificate

Laboratory-confirmed active influenza infection during the index hospitalization

Contraindication for vaccination (e.g., known allergy)

Inability to provide written informed consent

Trial design

Design model

Parallel

Treatments tested in this trial

  • Intrahospital seasonal influenza vaccination offer

    Biological/Vaccine

    Offer of bedside vaccination against seasonal influenza during the index hospitalization, administered in a standardized manner by trained treating physicians according to the latest STIKO recommendations and the respective product information. The appropriate vaccine is selected according to current recommendations (e.g., high-dose quadrivalent vaccine for patients aged 60 years and older, standard-dose quadrivalent vaccine otherwise). Vaccination is offered from September 1 to February 28 of the respective influenza season.

  • Standardized active influenza vaccination counseling

    Behavioral

    Standardized active counseling on influenza vaccination using a cardiovascular gain-framed information sheet, including the recommendation to be vaccinated and the opportunity to discuss vaccination with the treating physician. Counseling is provided to all patients in both arms after completion of the baseline 7C questionnaire and prior to randomization.

  • Standard of care discharge recommendation for ambulatory vaccination

    Behavioral

    Current standard of care in Germany: the recommendation to obtain ambulatory influenza vaccination from the primary care physician, stated in the discharge papers.

Treatment groups

482 Participants
are divided into 2 treatment groups
Group A: Intrahospital vaccination offerExperimental treatment 2 interventions
Group B: Active counseling alone (standard of care)Active comparator 2 interventions

Trial outcomes

Primary outcomes

1

Influenza vaccination rate at the end of the index influenza season

Proportion of patients vaccinated against seasonal influenza at the end of the index season (defined as March 31). For intervention group patients vaccinated during the index hospitalization, vaccination status is documented from inpatient medical records. For control group patients and intervention group patients who declined intrahospital vaccination, self-reported vaccination status is assessed by telephone interview beginning April 1 and cross-validated with data from the treating general practitioner.

Time frame
From randomization to the end of the index influenza season (March 31), up to approximately 7 months

Secondary outcomes

1

Influenza vaccination rate at the end of the post-index influenza season

Proportion of patients vaccinated against seasonal influenza at the end of the post-index season. For all patients, self-reported vaccination status is assessed by telephone interview beginning April 1 of the post-index season and cross-validated with data from the treating general practitioner.

Time frame
From randomization to the end of the post-index influenza season (March 31 of the following year), up to approximately 19 months
2

Association of the individual components of the 7C psychological antecedents of vaccination questionnaire with vaccination status

Association of the individual components of the 7C psychological antecedents of vaccination questionnaire (7-point scale, long version), assessed at baseline prior to active counseling, with vaccination status at the end of the index season. Assessed using univariate and multivariable regression models reporting odds ratios with 95% confidence intervals.

Time frame
Baseline (prior to counseling and randomization) and end of the index influenza season (March 31), up to approximately 7 months
3

Patient satisfaction with the offer of intrahospital influenza vaccination

Descriptive assessment of patient satisfaction with the intrahospital vaccination offer, based on a study-specific patient satisfaction questionnaire completed by patients in the intervention group.

Time frame
During the index hospitalization, up to approximately 14 days

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Stephan Baldus

Lead sponsor

University Hospital of Cologne

Sponsor institution

Sanofi

Collaborator

This trial is not recruiting at the moment. You can still explore other options: